MCG for Localization of Tachyarrhythmia's Origin

Not Applicable

Recruiting

• Conditions: Tachyarrhythmia; Paroxysmal Supraventricular Tachycardia; Atrial Tachycardia; Atrial Flutter; Premature Ventricular Contraction; Atrial Fibrillation
• Interventions: Device: Magnetocardiography

• Registration Number: NCT06327425
• Lead Sponsor: Qilu Hospital of Shandong University

Brief Summary

This is an exploratory research aiming to accurately identify the site of origin of tachyarrhythmia using Magnetocardiography (MCG), which will have guiding significance for early diagnosis, the formulation of treatment plans and preoperative positioning for radiofrequency ablation.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-02
• Study First Submitted: 2024-03-11
• Study Start: 2024-03-14
• Study First Submitted QC: 2024-03-21
• Study First Posted: 2024-03-25
• Last Update Submitted: 2024-08-19
• Last Update Posted: 2024-08-21
• Primary Completion: 2024-12
• Study Completion: 2025-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Age 18-79 years old;
• Those whose conditions are comparatively stable and who have been diagnosed by an attending physician （or physicians with higher qualifications） with paroxysmal supraventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, or premature ventricular contractions, and who are capable of performing MCG and cardiac electrophysiologic examinations after evaluation.
• Signed informed consent.

Exclusion Criteria

• Those with known structural heart disease such as cardiomyopathy and valvular disease;
• Those with history of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
• Those with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
• Those with obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
• Those with Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
• Those with malignant tumors;
• Professional athletes, pregnant or breastfeeding women, alcoholics;
• Those with acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
• Those with infectious diseases or communicable diseases;
• Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
• Unable to or fail to cooperate with the corresponding research requirements.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Patients with atrial tachycardia	Magnetocardiography	Patients with atrial tachycardia will receive dynamic ECG, MCG and cardiac electrophysiologic examinations.
Patients with atrial flutter	Magnetocardiography	Patients with atrial flutter will receive dynamic ECG, MCG and cardiac electrophysiologic examinations.

Primary Outcome Measures

Name	Time	Method
Efficacy of MCG to detect the site of origin of Tachyarrhythmia using cardiac electrophysiology as a reference standard.	12 month course of the disease	Sensitivity, specificity, and area under the ROC curve are performed for assessing the efficacy.

Trial Locations

Locations (1)

China, Shandong Qilu Hospital of Shandong University; 🇨🇳 Jinan, Shandong, China